Variables | Input values | Incremental costs (US $) | Incremental QALY † | ICER (US $ per QALY gained) |
---|---|---|---|---|
Base case | 466 | 0.0370 | 12,598 (₩14,198,501/QALY) | |
Cost ratio from Berry 2001 [27] | 483 | 0.0370 | 13,065 | |
NYHA class I | 0.049 | |||
NYHA class II | 0.049 | |||
NYHA class III | 0.120 | |||
NYHA class IV | 0.831 | |||
FCM price ± 15% (US $) | 136-184 | 370-562 | 0.0370 | 10,009-15,188 |
Total number of FCM vials ± 1 vial | 3-5 | 306-626 | 0.0370 | 8,282-16,915 |
CHF medical cost ± 25% (US $) | 1,185-1,975 | 421-512 | 0.0370 | 11370-13,827‡ |
Effect-onset time | 6th day | 466 | 0.0370 | 12,598 |
Baseline CHF patient distribution from the expert survey | 191 | 0.0370 | 5,165 | |
NYHA class II | 58.3% | |||
NYHA class III | 41.7% |